Montelukast Sodium
Product Images NDC 53002-1441

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Montelukast Sodium (NDC 53002-1441). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530021441)

Montelukast Sodium 10 mg tablets blister packaging label from RPK Pharmaceuticals, Inc., containing 30 tablets. The label includes dosing instructions to take one tablet daily or as directed, along with safety warnings and storage information. It also displays the NDC 53002-1441 and lot and expiration details.*

FDA Label Image

Image Of Figure 1 (Montelukast Fig1)

Line graph showing mean percent change from baseline over weeks in treatment for Montelukast Sodium tablets compared to placebo. The graph includes data points at 0, 3, 6, 9, 12, and 15 weeks, with a washout period indicated after 12 weeks. Montelukast Sodium shows a greater increase from baseline than placebo throughout treatment.*

FDA Label Image

Image Of Chemical Structure (Montelukast Str)

Chemical structure of Montelukast Sodium as depicted in the image, showing its molecular framework including chlorine, sulfur, carboxylate sodium salt, and hydroxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.